Title
Evaluation of the Magicplex™sepsis real-time test for the rapid diagnosis of bloodstream infections in adults
Date Issued
01 January 2019
Access level
open access
Resource Type
journal article
Author(s)
Zboromyrska Y.
Cobos-Trigueros N.
Almela M.
Vergara A.
Mata C.
Soriano A.
Mensa J.
Marco F.
Vila J.
Hospital Clínico de Barcelona
Universidad de Barcelona
Publisher(s)
Frontiers Media S.A.
Abstract
Sepsis is a serious health condition worldwide, affecting more than 30 million people globally each year. Blood culture (BC) is generally used to diagnose sepsis because of the low quantity of microbes occurring in the blood during such infections. However, ∼50% of bloodstream infections (BSI) give negative BC, this figure being higher for sepsis, which delays the start of appropriate antimicrobial therapy. This prospective study evaluated a multiplex real-time polymerase chain reaction, the Magicplex™ Sepsis test (MP), for the detection of pathogens from whole blood, comparing it to routine BC. We analyzed 809 blood samples from 636 adult patients, with 132/809 (16.3%) of the samples positive for one or more relevant microorganism according to BC and/or MP. The sensitivity and specificity of MP were 29 and 95%, respectively, while the level of agreement between BC and MP was 87%. The rate of contaminated samples was higher for BC (10%) than MP (4.8%) (P < 0.001). Patients with only MP-positive samples were more likely to be on antimicrobial treatment (47%) than those with only BC-positive samples (18%) (P = 0.002). In summary, the MP test could be useful in some clinical setting, such as among patients on antibiotic therapy. Nevertheless, a low sensitivity demonstrated impairs its use as a part of a routine diagnostic algorithm.
Volume
9
Issue
MAR
Language
English
OCDE Knowledge area
Hematología Enfermedades infecciosas
Scopus EID
2-s2.0-85064000376
PubMed ID
Source
Frontiers in Cellular and Infection Microbiology
ISSN of the container
22352988
Sponsor(s)
This study was supported by the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, and cofinanced by the European Regional Development Fund (ERDF) A Way to Achieve Europe and the Spanish Network for Research in Infectious Diseases (REIPI RD12/0015). This study was also supported by grant 2014SGR653 from the Departament d’Universitats, Recerca i Societat de la Informació of the Generalitat de Catalunya, as well as by funding from the Innovative Medicines Initiative (COMBACTE, grant agreement 115523), Ciber de Enfermedades Respiratorias (CibeRes CB06/06/0028), 2009 Support to Research Groups of Catalonia 911 and IDIBAPS (CERCA Programme/Generalitat de Catalunya). The funding sources had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. CC is the recipient of a postdoctoral grant (Strategic Plan for Research and Innovation in Health - PERIS 2016-2020). CM was working with the IZASA-Werfen Group during the undertaking of this study.
Sources of information: Directorio de Producción Científica Scopus